Imiquimod (Synonyms: 咪喹莫特; R 837)

目录号: HY-B0180 纯度: 99.96%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

Imiquimod (R 837) 是一种 toll 样受体7 (TLR7) 激动剂，作为一种免疫反应修饰剂。Imiquimod 在体内表现出抗病毒和抗肿瘤作用。Imiquimod 可用于外生殖器、肛周疣、癌症和 COVID-19 的研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Imiquimod Chemical Structure

CAS No. : 99011-02-6

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
100 mg	￥485	In-stock
200 mg	￥710	In-stock
500 mg	￥1213	In-stock
1 g		询价
5 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Imiquimod:

MCE 顾客使用本产品发表的 38 篇科研文献

: Imiquimod purchased from MCE. Usage Cited in: Nat Commun. 2016 May 25;7:11724. [Abstract]; Freshly prepared splenic B cells are left unstimulated (lanes 1 and 4), or stimulated by 10 μg/mL αIgM for 6 or 24 h (lanes 2 and 3), or by 1 μg/mL IMQ for 6, 24, 48 and 72 h (lanes 5-8), or by αIgM and IMQ for 24 or 48 h (lanes 9+10), respectively.

Imiquimod 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Toll-like Receptor (TLR) 亚型特异性产品:

查看所有亚型

TLR3 TLR8 TLR9 TLR2 TLR4 TLR7 TLR1 TLR6

查看 HSV 亚型特异性产品:

查看所有亚型

HSV-1 HSV-2 HSV

生物活性
纯度 & 产品资料
参考文献

生物活性

Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19^[1]^[2].

IC₅₀ & Target^[1]^[3]

TLR7

HSV-1

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A-375	IC₅₀	70.3 μM Compound: Imiquimod	Cytotoxicity against human A375 cells after 96 hrs by MTT assay Cytotoxicity against human A375 cells after 96 hrs by MTT assay	[PMID: 19278757]
A-375	IC₅₀	70.3 μM Compound: imiquimod	Cytotoxicity against human A375 cells after 96 hrs by MTT assay Cytotoxicity against human A375 cells after 96 hrs by MTT assay	[PMID: 18513976]
HEK293	EC₅₀	> 270 μM Compound: 1	Agonist activity at human TLR8 transfected in HEK cells assessed as NFkappaB induction after 24 hrs by specific secreted alkaline phosphatase gene assay Agonist activity at human TLR8 transfected in HEK cells assessed as NFkappaB induction after 24 hrs by specific secreted alkaline phosphatase gene assay	[PMID: 22837811]
HEK293	EC₅₀	10.7 μM Compound: 1	Agonist activity at human TLR-7 expressed in HEK293 cells after 24 hrs by SEAP reporter gene assay Agonist activity at human TLR-7 expressed in HEK293 cells after 24 hrs by SEAP reporter gene assay	[PMID: 24383475]
HEK293	EC₅₀	12.1 μM Compound: 1	Agonist activity at human TLR7 transfected in HEK cells assessed as NFkappaB induction after 24 hrs by specific secreted alkaline phosphatase gene assay Agonist activity at human TLR7 transfected in HEK cells assessed as NFkappaB induction after 24 hrs by specific secreted alkaline phosphatase gene assay	[PMID: 22837811]
HEK293	EC₅₀	2.12 μM Compound: 1	Agonist activity at human TLR7 expressed in NF-kappaB-stimulated HEK293 cells assessed as induction of secreted alkaline phosphatase expression by reporter gene assay Agonist activity at human TLR7 expressed in NF-kappaB-stimulated HEK293 cells assessed as induction of secreted alkaline phosphatase expression by reporter gene assay	[PMID: 20481492]
HEK293	EC₅₀	6.2 μM Compound: 1	Agonist activity at human TLR7 in HEK293 cells cotransfected with SEAP reporter gene assessed as activity of SEAP incubated for 24 hrs by quanti-blue staining based SEAP reporter gene assay Agonist activity at human TLR7 in HEK293 cells cotransfected with SEAP reporter gene assessed as activity of SEAP incubated for 24 hrs by quanti-blue staining based SEAP reporter gene assay	[PMID: 31247373]
LS174T	IC₅₀	34.4 μM Compound: imiquimod	Cytotoxicity against human LS174T cells after 96 hrs by MTT assay Cytotoxicity against human LS174T cells after 96 hrs by MTT assay	[PMID: 18513976]
MCF7	IC₅₀	145 μM Compound: imiquimod	Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay Cytotoxicity against human MCF7 cells after 96 hrs by MTT assay	[PMID: 18513976]
Raji	IC₅₀	139 μM Compound: imiquimod	Cytotoxicity against human Raji cells after 96 hrs by MTT assay Cytotoxicity against human Raji cells after 96 hrs by MTT assay	[PMID: 18513976]

体内研究
(In Vivo)

Lmiquimod (IMQ) 可用于诱导银屑病模型^[5]。

诱导银屑病模型^[5]

致病原理

Lmiquimod (IMQ) 可诱发类似于斑块型银屑病的发炎鳞状皮肤病变。IMQ 诱导表皮表达 IL-23、IL-17A 和 IL-17F，以及脾Th17 细胞的增加。

具体造模方法：

小鼠：BALB/c • 雄性 • 8 周龄
给药方式：3.125 mg/day • 局部用于皮肤 • 6 天

Note

造模成功指标

组织学改变: 诱导小鼠背部皮肤开始出现红斑、鳞屑和增厚迹象。
导致角质形成细胞过度增殖并扰乱表皮分化（角化不全）。

相关产品： /

拮抗产品： /

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/c mice (8-11 week) ^[5]
Dosage:	3.125 mg/day, 6 day
Administration:	skin
Result:	Induced the back skin of the mice started to display signs of erythema, scaling, and thickening. Resulted in hyperproliferative keratinocytes and a disturbed epidermal differentiation (parakeratosis).

Clinical Trial

分子量

240.30

Formula

C₁₄H₁₆N₄

CAS 号

99011-02-6

性状

固体

颜色

White to off-white

中文名称

咪喹莫特

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

溶解性数据

细胞实验：

DMSO 中的溶解度 : 3.28 mg/mL (13.65 mM; ultrasonic and warming and adjust pH to 7 with 1 M HCL and heat to 60°C; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

H₂O 中的溶解度 : 2.64 mg/mL (10.99 mM; 超声助溶; 酸性条件溶解 (HCL 调节，pH≈2))

Methanol 中的溶解度 : < 1 mg/mL (insoluble)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	4.1615 mL	20.8073 mL	41.6146 mL
5 mM	0.8323 mL	4.1615 mL	8.3229 mL
10 mM	0.4161 mL	2.0807 mL	4.1615 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用， -20°C储存时，请在1年内使用。

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

计算结果

工作液所需浓度 : mg/mL

纯度 & 产品资料

纯度: 99.96%

选择批次：

Data Sheet (632 KB) SDS (419 KB)

COA (293 KB) LCMS (120 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Athina Angelopoulou, et al. Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19. Environ Res. 2020 Sep; 188: 109858. [Content Brief]

[2]. Aditya K Gupta, et al. Imiquimod: a review. J Cutan Med Surg. Nov-Dec 2002;6(6):554-60. [Content Brief]

[3]. Yuji Kan, et al. Imiquimod suppresses propagation of herpes simplex virus 1 by upregulation of cystatin A via the adenosine receptor A1 pathway. J Virol. 2012 Oct;86(19):10338-46. [Content Brief]

[4]. Michael P Schön, et al. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. J Invest Dermatol. 2006 Jun;126(6):1338-47. [Content Brief]

[5]. Leslie van der Fits, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol. 2009, 182, 9. [Content Brief]

[6]. Ajla Smajlović, et al. Molecular and histopathological profiling of imiquimod induced dermatosis in Swiss Wistar rats: contribution to the rat model for novel anti-psoriasis treatments. Mol Biol Rep. 2021, 48, 5. [Content Brief]

[7]. Sangseo Kim, et al. Development and Optimization of Imiquimod-Loaded Nanostructured Lipid Carriers Using a Hybrid Design of Experiments Approach. Int J Nanomedicine. 2023. [Content Brief]

Imiquimod 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	4.1615 mL	20.8073 mL	41.6146 mL	104.0366 mL
	5 mM	0.8323 mL	4.1615 mL	8.3229 mL	20.8073 mL
	10 mM	0.4161 mL	2.0807 mL	4.1615 mL	10.4037 mL

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

产品名称：

* 需求量：

* 客户姓名：

* Email：

* 电话：

* 公司或机构名称：

留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。

站点地图隐私声明

沪ICP备15051369号-4

上海工商

沪公网安备31011502019417

沪(浦)应急管危经许[2021]201709(QFYS)

营业执照（三证合一）

Imiquimod (Synonyms: 咪喹莫特; R 837)

Customer Review

Other Forms of Imiquimod:

MCE 顾客使用本产品发表的 38 篇科研文献